Advertisement
![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
Document › Details
CRISPR Therapeutics AG. (2/12/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results". Zug & Cambridge, MA.
Original document
accessed by [iito] on 2020-02-26
Record changed: 2020-03-02 |
Advertisement

More documents for CRISPR Therapeutics (Group)
- [1] CRISPR Therapeutics AG. (10/28/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results". Zug & Cambridge, MA....
- [2] CRISPR Therapeutics AG. (6/30/20). "Press Release: CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares". Zug & Cambridge, MA....
- [3] CRISPR Therapeutics AG. (6/29/20). "Press Release: CRISPR Therapeutics Announces Proposed Offering of Common Shares". Zug & Cambridge, MA....
- [4] CRISPR Therapeutics AG. (6/25/20). "Press Release: CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility". Zug & Cambridge, MA....
- [5] CRISPR Therapeutics AG. (5/11/20). "Press Release: CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the Treatment of Severe Hemoglobinopathies". Zug, Cambridge, MA...
- [6] CRISPR Therapeutics AG. (5/7/20). "Press Release: CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference". Zug & Cambridge, MA....
- [7] CRISPR Therapeutics AG. (2/26/20). "Press Release: CRISPR Therapeutics Proposes Changes to the Board of Directors". Zug & Cambridge, MA....
- [8] CRISPR Therapeutics AG. (11/20/19). "Press Release: CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares". Zug & Cambridge, MA....
- [9] CRISPR Therapeutics AG. (11/19/19). "Press Release: CRISPR Therapeutics Announces Proposed Public Offering of Common Shares". Zug & Cambridge, MA....
- [10] CRISPR Therapeutics AG. (11/19/19). "Press Release: CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies". Zug...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top